A research team led by investigators from the NIH and Global Good has developed a computer algorithm that can analyze digital images of a woman's cervix and accurately identify precancerous changes that require medical attention. This artificial intelligence approach, called automated visual evaluation, has the potential to revolutionize cervical cancer screening, particularly in low-resource settings.
UroGen Pharma Ltd. announced topline results from the ongoing pivotal phase III OLYMPUS clinical trial of UGN-101 (mitomycin gel) for instillation, an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cancer.
A steady, 25-year decline has resulted in a 27% drop in the overall cancer death rate in the United States, translating to approximately 2.6 million fewer cancer deaths between 1991 and 2016. The data come from Cancer Statistics, 2019, the American Cancer Society's widely-quoted annual report on cancer rates and trends.
The Department of Defense Breast Cancer Research Program has published information to allow investigators time to plan and develop applications.
José Baselga was appointed to a key role in driving scientific innovation in oncology at AstraZeneca, the company said.
Cindy Perettie was named CEO of Foundation Medicine Inc. effective Feb. 4.
Lori Hazlehurst has been named as the associate director for Basic Research at the WVU Cancer Institute. In this role, she will work closely with Richard Goldberg, Institute director, and the leadership team of the WVU Cancer Institute to implement strategic goals to increase the impact of basic and translational cancer research at WVU. The primary strategy is to increase the number of NIH funded investigators focused on cancer research at WVU.
Eli Lilly and Co. and Loxo Oncology Inc. announced a definitive agreement for Lilly to acquire Loxo Oncology for $235 per share in cash, or approximately $8 billion.
Nanobiotix and MD Anderson Cancer Center announced a large-scale, comprehensive clinical research collaboration to evaluate innovative strategies for treating patients with head and neck, pancreatic, thoracic, lung, gastrointestinal, and genitourinary cancers.
Adaptive Biotechnologies and Genentech said they have entered into a worldwide collaboration and license agreement to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers.
